KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Equity Income: 2017-2025

Historic Equity Income for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Sep 2025 value amounting to $2.0 million.

  • Teva Pharmaceutical Industries' Equity Income fell 33.33% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 175.00%. This contributed to the annual value of $1.0 million for FY2024, which is 50.00% down from last year.
  • Teva Pharmaceutical Industries' Equity Income amounted to $2.0 million in Q3 2025, which was up 100.00% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Equity Income ranged from a high of $21.0 million in Q1 2022 and a low of -$5.0 million during Q3 2021.
  • For the 3-year period, Teva Pharmaceutical Industries' Equity Income averaged around $666,667, with its median value being $1.0 million (2025).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Equity Income surged by 600.00% in 2022, and later tumbled by 900.00% in 2024.
  • Teva Pharmaceutical Industries' Equity Income (Quarterly) stood at -$5.0 million in 2021, then skyrocketed by 80.00% to $1.0 million in 2022, then remained steady at $1.0 million in 2023, then surged by 100.00% to $3.0 million in 2024, then tumbled by 33.33% to $2.0 million in 2025.
  • Its Equity Income stands at $2.0 million for Q3 2025, versus $1.0 million for Q2 2025 and -$500,000 for Q1 2025.